Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on the development of Oxy210 (oxysterol), a small-molecule antifibrotic. It is currently being evaluated in preclinical studies for the treatment of non-alcoholic steatohepatitis idiopathic, pulmonary fibrosis including chronic inflammation.
Lead Product(s): Oxysterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Oxy210
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Metaba
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2024
Details:
Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of NASH that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice.
Lead Product(s): Oxy210
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020